Brainomix and Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis

Brainomix and Boehringer Ingelheim are broadening their strategic partnership in pulmonary fibrosis, building on strong initial results that demonstrated e-Lung's potential to enable earlier diagnosis of progressive pulmonary fibrosis (PPF). The next phase, PROGRESS-PPF, is a prospective multicenter study designed to generate evidence of e-Lung's clinical impact at scale, with deployments planned across numerous sites in the US.